LiveGrow Bio and T3 BioScience announce plans to advance a gram-negative biopesticide in 2025
livegrowbio
2025.01.08
LiveGrow Bio, a provider of advanced microbial formulation and manufacturing solutions, and T3 BioScience, Inc., a developer of novel microbial crop protection products, announced plans to collaborate in 2025 on the development of a new biopesticide derived from a Gram-negative bacterial strain.
T3 BioScience, a University of Wisconsin Research Foundation startup was established in 2012 and guided by the pioneering research of Dr. Ching-Hong Yang at the University of Wisconsin-Milwaukee (UWM), focuses on creating products capable of reducing the need for antibiotics in agriculture. Through its proprietary discovery platform, PROMISA, T3 BioScience has identified novel bacteria with performance comparable to traditional antibiotics and chemical solutions.
The collaboration will leverage LiveGrow Bio’s proprietary formulation technology to provide T3 BioScience a commercially viable product formulation for biocontrol living bacteria early in the development process. This approach aims to reduce the time and cost traditionally associated with bringing Gram-negative microbial solutions to market.
LiveGrow Bio, a provider of advanced microbial formulation and manufacturing solutions, and T3 BioScience, Inc., a developer of novel microbial crop protection products, announced plans to collaborate in 2025 on the development of a new biopesticide derived from a Gram-negative bacterial strain.
T3 BioScience, a University of Wisconsin Research Foundation startup was established in 2012 and guided by the pioneering research of Dr. Ching-Hong Yang at the University of Wisconsin-Milwaukee (UWM), focuses on creating products capable of reducing the need for antibiotics in agriculture. Through its proprietary discovery platform, PROMISA, T3 BioScience has identified novel bacteria with performance comparable to traditional antibiotics and chemical solutions.
The collaboration will leverage LiveGrow Bio’s proprietary formulation technology to provide T3 BioScience a commercially viable product formulation for biocontrol living bacteria early in the development process. This approach aims to reduce the time and cost traditionally associated with bringing Gram-negative microbial solutions to market.
Read more here.